Applied Health Economics and Health Policy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis
ConclusionsProstate cancer reconfigurations had the highest probability of being cost-effective. It is not clear, however, whether the prostate results can be considered in isolation, given the reconfigurations occurred simultaneously with other system changes, and healthcare delivery in the NHS is highly networked and collaborative. Routine collection of quality-of-life measures such as the EQ-5D-5L would have improved the analysis. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 22, 2022 Category: Health Management Source Type: research

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
ConclusionsThe incremental cost-effectivenes ratio was well below the applicable threshold for diseases with a high burden of disease in the Netherlands ( €80,000). At this threshold, larotrectinib was estimated to be a cost-effective treatment for patients with tropomyosin receptor kinase fusion-positive cancer compared with current standard of care in the Netherlands. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 18, 2022 Category: Health Management Source Type: research

Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia
ConclusionA 'soft opt-out' organ donation system would return a cost saving for the healthcare system, a net gain in QALYs, and prevention of a significant number of deaths. Advantageous budgetary impact is important, but understanding the aversion for a ‘soft opt-out’ system in Australia is also important and remains a priority for further research. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 18, 2022 Category: Health Management Source Type: research

UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update
AbstractLower urinary tract symptoms (LUTS) commonly occur as a consequence of benign prostatic hyperplasia (BPH), also known as prostate enlargement. Treatments for this can involve electrosurgical removal of a section of the prostate via transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), or prostatic urethral lift using the UroLift system. The UroLift system implants to pull excess prostatic tissue away so that it does not narrow or block the urethra. In this way, the device is designed to relieve symptoms of urinary outflow obstruction without cutting or removing tissue. N...
Source: Applied Health Economics and Health Policy - July 18, 2022 Category: Health Management Source Type: research

Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 15, 2022 Category: Health Management Source Type: research

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
ConclusionsResults suggest that indication development is prioritised according to clinical value and disease prevalence. Countries employ different mechanisms to account for each indication ’s differential benefit, e.g., weighted-average prices (Germany, France, Australia), differential discounts (England, Scotland), clinical restrictions, and MEAs (England, Scotland, Australia, Canada).Value-basedindication-specific pricing can help to align the benefit and price for multi-indication cancer drugs. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 11, 2022 Category: Health Management Source Type: research

Including Pharmaceuticals in Bundled Payments
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - July 8, 2022 Category: Health Management Source Type: research

Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study
AbstractEconomic evaluations have increasingly sought to understand how funding decisions within care sectors impact health inequalities. However, there is a disconnect between the methods used by researchers (e.g., within universities) and analysts (e.g., within publicly funded commissioning agencies), compared to evidence needs of decision makers in regard to how health inequalities are accounted for and presented. Our objective is to explore how health inequality is defined and quantified in different contexts. We focus on how specific approaches have developed, what similarities and differences have emerged, and consid...
Source: Applied Health Economics and Health Policy - June 29, 2022 Category: Health Management Source Type: research

Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO)
AbstractWorldwide, population obesity levels are at their highest recorded levels, having nearly tripled between 1975 and 2016. This leads to substantial pressure on health systems, a negative impact on economic development, and results in adverse physical and mental health outcomes. There are many economic reasons why reducing population obesity should be a priority, and global targets have been set with many governments pledging to reduce obesity levels by 2030. To achieve these targets, a ‘system-wide’ approach has been widely advocated in direct recognition of the wide-ranging complex interacting determinants of th...
Source: Applied Health Economics and Health Policy - June 20, 2022 Category: Health Management Source Type: research

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
AbstractThere is growing interest in cost-effectiveness thresholds as a tool to inform resource allocation decisions in health care. Studies from several countries have sought to estimate health system opportunity costs, which supply-side cost-effectiveness thresholds are intended to represent. In this paper, we consider the role of empirical estimates of supply-side thresholds in policy-making. Recent studies estimate the cost per unit of health based on average displacement or outcome elasticity. We distinguish the types of point estimates reported in empirical work, including marginal productivity, average displacement,...
Source: Applied Health Economics and Health Policy - June 7, 2022 Category: Health Management Source Type: research

Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians
ConclusionGiven the role of clinicians in the healthcare system, as agents both for patients and for providers, more needs to be done to remove informational asymmetries and improve clinician cost awareness. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - May 24, 2022 Category: Health Management Source Type: research

ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients
ConclusionENTIMOS is a flexible model of patient flow and care delivery in infusion centres serving MS patients. It allows users to simulate specific local settings and therefore identify measures that are necessary to avoid clinically significant treatment delay resulting in suboptimal care. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - May 19, 2022 Category: Health Management Source Type: research

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women
ConclusionCDK4/6i (ribociclib and palbociclib) therapy  is not a cost-effective treatment option for MBC patients. A 72% reduction in the reimbursement rate for fulvestrant monotherapy will make it a cost-effective treatment option in the Indian context. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - May 10, 2022 Category: Health Management Source Type: research

Centralised Pharmaceutical Procurement: Learnings from Six European Countries
This article comparatively describes key features of national centralised pharmaceutical procurement (CPP) systems of six European countries (Cyprus, Denmark, Estonia, Italy, Norway and Portugal). Additionally, it aims to identify benefits, challenges and prerequisites for successful CPP, with a view to offering learnings for other countries. Information was collected based on literature and interviews with national procurement experts. While all countries studied established a designated procurement entity, other institutional and organisational features of the CPP systems vary across the countries. All CPP systems apply ...
Source: Applied Health Economics and Health Policy - May 6, 2022 Category: Health Management Source Type: research

Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
ConclusionTriple therapy with BGF was predicted to improve outcomes and be a cost-effective treatment option compared with LAMA/LABA therapies for patients with moderate to very severe COPD in China. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - April 28, 2022 Category: Health Management Source Type: research